{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:52:59Z","timestamp":1772254379961,"version":"3.50.1"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1055\/a-2441-8902","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:10:27Z","timestamp":1731456627000},"page":"286-289","source":"Crossref","is-referenced-by-count":2,"title":["Off-Label Dosing of Direct Oral Anticoagulants: Prescribing Error or Opportunity in Treating Patients with Atrial Fibrillation?"],"prefix":"10.1055","volume":"125","author":[{"given":"Daniela","family":"Poli","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"42","key":"ref3","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/eurheartj\/ehz726","article-title":"The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism","volume":"40","author":"S V Konstantinides","year":"2019","journal-title":"Eur Heart J"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants","volume":"76","author":"A J Camm","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s11606-020-05777-3","article-title":"Comparative safety and effectiveness of direct-acting oral anticoagulants versus warfarin: a National Cohort Study of Nursing Home Residents","volume":"35","author":"M Alcusky","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/europace\/eux316","article-title":"Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry","volume":"20","author":"M Ruiz Ortiz","year":"2018","journal-title":"Europace"},{"issue":"07","key":"ref9","first-page":"777","article-title":"The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2","volume":"69","author":"M V Huisman","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.amjmed.2019.01.025","article-title":"Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation","volume":"132","author":"R Arbel","year":"2019","journal-title":"Am J Med"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3390\/jcm13072009","article-title":"Inappropriate underdosing of direct oral anticoagulants in atrial fibrillation patients: results from the START2-AF Registry","volume":"13","author":"D Poli","year":"2024","journal-title":"J Clin Med"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11239-018-1690-6","article-title":"Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events","volume":"46","author":"R Chopard","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"16","key":"ref13","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"J Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1055\/a-2021-8910","article-title":"Direct oral anticoagulants in the very elderly","volume":"123","author":"J W Eikelboom","year":"2023","journal-title":"Thromb Haemost"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/a-2365-8681","article-title":"Timing of off-label dosing of direct oral anticoagulants in three large health systems","author":"G C Herron","year":"2024","journal-title":"Thromb Haemost"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.062","article-title":"Clinical effects of off-label reduced doses of direct oral anticoagulants: a systematic review and meta-analysis","volume":"362","author":"M Q Pereira","year":"2022","journal-title":"Int J Cardiol"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/heartjnl-2022-321114","article-title":"Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"109","author":"V Caso","year":"2023","journal-title":"Heart"},{"issue":"9921","key":"ref18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejim.2023.10.010","article-title":"Anticoagulation in atrial fibrillation. A large real-world update","volume":"121","author":"M Bo","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s11739-017-1678-9","article-title":"Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago","volume":"12","author":"G Palareti","year":"2017","journal-title":"Intern Emerg Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.thromres.2015.12.001","article-title":"Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics","volume":"137","author":"S Testa","year":"2016","journal-title":"Thromb Res"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"D A Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00228-019-02693-2","article-title":"Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation","volume":"75","author":"M Mikli\u010d","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/a-1981-1763","article-title":"Assessment of DOAC in GEriatrics (Adage Study): rivaroxaban\/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients","volume":"123","author":"G Foulon-Pinto","year":"2023","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/bloodadvances.2023012408","article-title":"Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study","volume":"8","author":"S Testa","year":"2024","journal-title":"Blood Adv"},{"issue":"18","key":"ref26","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/bloodadvances.2024013126","article-title":"More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study","volume":"8","author":"G Palareti","year":"2024","journal-title":"Blood Adv"},{"issue":"18","key":"ref27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"K Okumura","year":"2020","journal-title":"N Engl J Med"},{"issue":"09","key":"ref28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1055\/s-0044-1785511","article-title":"Pharmacokinetics of edoxaban 15\u2009mg in very elderly patients with nonvalvular atrial fibrillation: a subanalysis of the ELDERCARE-AF study","volume":"124","author":"T Yamashita","year":"2024","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2441-8902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:16:16Z","timestamp":1740528976000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2441-8902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":28,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2441-8902","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}